Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.
Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade JA, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM; IPF-PRO Registry investigators. Todd JL, et al. Among authors: hesslinger c. Lung. 2022 Feb;200(1):19. doi: 10.1007/s00408-022-00516-3. Lung. 2022. PMID: 35166906 Free PMC article. No abstract available.
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Todd JL, et al. Among authors: hesslinger c. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z. Respir Res. 2019. PMID: 31640794 Free PMC article. Clinical Trial.
Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort.
Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, Noth I, Newby LK, Lasky JA, Olman MA, Hesslinger C, Leonard TB, Palmer SM, Belperio JA; IPF-PRO Registry investigators. Todd JL, et al. Among authors: hesslinger c. BMC Pulm Med. 2020 Mar 14;20(1):64. doi: 10.1186/s12890-020-1103-4. BMC Pulm Med. 2020. PMID: 32171287 Free PMC article.
Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort.
Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade JA, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM; IPF-PRO Registry investigators. Todd JL, et al. Among authors: hesslinger c. Lung. 2022 Feb;200(1):11-18. doi: 10.1007/s00408-021-00505-y. Epub 2022 Jan 23. Lung. 2022. PMID: 35066606 Free PMC article.
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Richeldi L, et al. Among authors: hesslinger c. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569036 Clinical Trial.
In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase.
Lehner MD, Marx D, Boer R, Strub A, Hesslinger C, Eltze M, Ulrich WR, Schwoebel F, Schermuly RT, Barsig J. Lehner MD, et al. Among authors: hesslinger c. J Pharmacol Exp Ther. 2006 Apr;317(1):181-7. doi: 10.1124/jpet.105.098673. Epub 2005 Dec 20. J Pharmacol Exp Ther. 2006. PMID: 16368897
27 results